Megan Robinson

A novel platform to enable the high-throughput derivation and characterization of feeder-free human iPSCs

Bahram Valamehr, M. Robinson, Thuy T. Le, 2012, Scientific Reports.

Platform for Induction and Maintenance of Transgene-free hiPSCs Resembling Ground State Pluripotent Stem Cells

Bahram Valamehr, A. Medcalf, F. Vranceanu, 2014, Stem cell reports.

Myogenic Differentiation of Muscular Dystrophy‐Specific Induced Pluripotent Stem Cells for Use in Drug Discovery

Bahram Valamehr, M. Bennett, Ramzey J Abujarour, 2014, Stem cells translational medicine.

Abstract 3576: FT500, an off-the-shelf NK cell cancer immunotherapy derived from a master pluripotent cell line, enhances T-cell activation and recruitment to overcome checkpoint blockade resistance

Paul C. Rogers, Raedun Clarke, M. Ge, 2018, Immunology.

Global Genechip Profiling to Identify Genes Responsive to p53-Induced Growth Arrest and Apoptosis in Human Lung Carcinoma Cells

T. Lawrence, M. Swaroop, P. Jiang, 2003, Cancer biology & therapy.

iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti–PD-1 therapy

Paul C. Rogers, D. Kaufman, Raedun Clarke, 2020, Science Translational Medicine.

Optimized Surface Markers for the Prospective Isolation of High-Quality hiPSCs using Flow Cytometry Selection

Bahram Valamehr, F. Vranceanu, M. Robinson, 2013, Scientific Reports.

Novel Miniaturized Drug Conjugate Leverages HSP90-driven Tumor Accumulation to Overcome PI3K Inhibitor Delivery Challenges to Solid Tumors

R. Wooster, Sara Movassaghian, M. Bilodeau, 2020, Molecular Cancer Therapeutics.